Piet Wigerinck
Director/Board Member at IPSEN
Net worth: 81 004 $ as of 2024-03-30
Profile
Currently, Piet Wigerinck is Chief Scientific Officer of Galapagos NV. He is also on the board of Ipsen SA and Ipsen Pharma SAS. In the past he was Vice President-Drug Discovery & Early Development at Tibotec Pharmaceuticals and Vice President of Drug Discovery & Development Solutions Ltd. Dr. Wigerinck received a doctorate from Katholieke Universiteit Leuven.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IPSEN SA
0.00% | 2022-12-30 | 680 ( 0.00% ) | 81 004 $ | 2024-03-30 |
Piet Wigerinck active positions
| Companies | Position | Start |
|---|---|---|
| IPSEN | Director/Board Member | 2018-04-30 |
University Hospital Antwerp
 University Hospital Antwerp Hospital/Nursing ManagementHealth Services University Hospital Antwerp provides clinical, patient care, academic training and scientific research services. The company was is headquartered in Belgium. | Director/Board Member | - |
miDIAGNOSTICS NV
 miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services miDIAGNOSTICS NV develops a computer chip powered portable medical laboratory. The company is headquartered in Leuven, Belgium. | Director/Board Member | - |
Atriva Therapeutics GmbH
 Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Director/Board Member | - |
| UZA Foundation | Director/Board Member | - |
Former positions of Piet Wigerinck
| Companies | Position | End |
|---|---|---|
| GALAPAGOS NV | Chief Tech/Sci/R&D Officer | 2021-12-30 |
Xinvento BV
 Xinvento BV BiotechnologyHealth Technology Part of Rhythm Pharmaceuticals, Inc., Xinvento BV is a Dutch biotech company that develops therapies for congenital hyperinsulinism. The private company is based in Amsterdam, Netherlands. The company was founded in 2021 by Claudine van der Sande, Sarah Hafith-de Boer, Piet Wigerinck. Claudine van der Sande has been the CEO since 2021. Xinvento was acquired by Rhythm Pharmaceuticals Netherlands BV on February 27, 2023 for $222.43 million. | Founder | - |
| Tibotec-Virco Comm Va | Corporate Officer/Principal | - |
Drug Discovery & Development Solutions Ltd.
 Drug Discovery & Development Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Drug Discovery & Development Solutions Ltd. engages in the provision of financial services. The company is headquartered in Singapore. | Corporate Officer/Principal | - |
Training of Piet Wigerinck
| Katholieke Universiteit Leuven | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| IPSEN | Health Technology |
| GALAPAGOS NV | Health Technology |
| Private companies | 7 |
|---|---|
University Hospital Antwerp
University Hospital Antwerp Hospital/Nursing ManagementHealth Services University Hospital Antwerp provides clinical, patient care, academic training and scientific research services. The company was is headquartered in Belgium. | Health Services |
miDIAGNOSTICS NV
miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services miDIAGNOSTICS NV develops a computer chip powered portable medical laboratory. The company is headquartered in Leuven, Belgium. | Commercial Services |
Drug Discovery & Development Solutions Ltd.
Drug Discovery & Development Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Drug Discovery & Development Solutions Ltd. engages in the provision of financial services. The company is headquartered in Singapore. | Commercial Services |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
| Tibotec-Virco Comm Va | |
Xinvento BV
Xinvento BV BiotechnologyHealth Technology Part of Rhythm Pharmaceuticals, Inc., Xinvento BV is a Dutch biotech company that develops therapies for congenital hyperinsulinism. The private company is based in Amsterdam, Netherlands. The company was founded in 2021 by Claudine van der Sande, Sarah Hafith-de Boer, Piet Wigerinck. Claudine van der Sande has been the CEO since 2021. Xinvento was acquired by Rhythm Pharmaceuticals Netherlands BV on February 27, 2023 for $222.43 million. | Health Technology |
| UZA Foundation |
- Stock Market
- Insiders
- Piet Wigerinck
